Literature DB >> 17942757

Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.

Sumita Bhaduri-McIntosh1, Marisa J Rotenberg, Benjamin Gardner, Marie Robert, George Miller.   

Abstract

Answers to questions about frequency and repertoire of immune cells, relative contributions made by different types of immune cells toward the total Epstein-Barr virus (EBV)-directed response and the variation of such responses in healthy persons have been elusive because of disparities in assays, antigen presenting cells, and antigenic sources used in previous experiments. In this study, we addressed these questions using an assay that allowed direct comparison of responses generated by different types of cells of the immune system. This short-term (20-hour) ex vivo assay measured interferon-gamma production by blood cells in response to autologous EBV-transformed lymphoblastoid cell lines (LCLs). Our experiments defined the variation in responses among persons and clearly distinguished 10 healthy EBV-immune from 10 healthy EBV-naive persons. In EBV-immune persons, 33% of responding cells were CD4(+), 43.3% were CD8(+), and 12.9% were gamma-delta T cells. LCL-reactive CD8(+) T cells were only 1.7-fold more frequent than similarly reactive CD4(+)T cells. Responses by gamma-delta T cells were 6-fold higher in seropositive than in seronegative persons. Our findings emphasize the importance of CD4(+) and gamma-delta T-cell responses and have implications for immunotherapy and for identifying defects in T-cell populations that might predispose to development of EBV-associated lymphomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942757      PMCID: PMC2214741          DOI: 10.1182/blood-2007-07-101907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection.

Authors:  Melissa L Precopio; John L Sullivan; Courtney Willard; Mohan Somasundaran; Katherine Luzuriaga
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

2.  Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.

Authors:  Donna Hochberg; Jaap M Middeldorp; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

3.  Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.

Authors:  Kui Shin Voo; Tihui Fu; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Rong-Fu Wang
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

Review 4.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

5.  Long-term T-cell-mediated immunity to Epstein-Barr virus.

Authors:  A B Rickinson; D J Moss; L E Wallace; M Rowe; I S Misko; M A Epstein; J H Pope
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

6.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

Authors:  Patrizia Comoli; Massimo Labirio; Sabrina Basso; Fausto Baldanti; Paolo Grossi; Milena Furione; Mario Viganò; Roberto Fiocchi; Giorgio Rossi; Fabrizio Ginevri; Bruno Gridelli; Antonia Moretta; Daniela Montagna; Franco Locatelli; Giuseppe Gerna; Rita Maccario
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

7.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

8.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Authors:  Andrew D Hislop; Nicola E Annels; Nancy H Gudgeon; Alison M Leese; Alan B Rickinson
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.

Authors:  Elisabeth Amyes; Chris Hatton; Damien Montamat-Sicotte; Nancy Gudgeon; Alan B Rickinson; Andrew J McMichael; Margaret F C Callan
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  12 in total

1.  B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.

Authors:  Siva Koganti; Amanda de la Paz; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

Review 2.  Novel strategies for adoptive therapy following HLA disparate transplants.

Authors:  Richard J O'Reilly; Aisha Hasan; Ekaterina Doubrovina; Guenther Koehne; Susan Prockop
Journal:  Best Pract Res Clin Haematol       Date:  2011-09       Impact factor: 3.020

Review 3.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Efficient Culture of Human Naive and Memory B Cells for Use as APCs.

Authors:  Kuei-Ying Su; Akiko Watanabe; Chen-Hao Yeh; Garnett Kelsoe; Masayuki Kuraoka
Journal:  J Immunol       Date:  2016-10-10       Impact factor: 5.422

5.  Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.

Authors:  Heather M Long; Alison M Leese; Odette L Chagoury; Shawn R Connerty; Jared Quarcoopome; Laura L Quinn; Claire Shannon-Lowe; Alan B Rickinson
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

6.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

7.  Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.

Authors:  Sameer Lapsia; Siva Koganti; Salvatore Spadaro; Ramona Rajapakse; Anupama Chawla; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2015-08-31       Impact factor: 2.327

8.  Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.

Authors:  Jennifer S Sims; Boris Grinshpun; Yaping Feng; Timothy H Ung; Justin A Neira; Jorge L Samanamud; Peter Canoll; Yufeng Shen; Peter A Sims; Jeffrey N Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-03       Impact factor: 11.205

9.  Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.

Authors:  Sandra A Calarota; Antonella Chiesa; Paola Zelini; Giuditta Comolli; Lorenzo Minoli; Fausto Baldanti
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 10.  Laboratory assays for Epstein-Barr virus-related disease.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.